SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock opened at $1.21 on Thursday. SELLAS Life Sciences Group has a 1-year low of $0.77 and a 1-year high of $1.84. The stock’s 50-day moving average is $1.20 and its 200 day moving average is $1.17. The company has a market cap of $85.16 million, a P/E ratio of -1.75 and a beta of 2.43.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.